BioMark -Model SSAT1 -Diagnostics Liquid Biopsy Assay
BioMark’s initial liquid biopsy assay detects SSAT1 using an FDA approved drug. SSAT1 is an enzyme with elevated levels in numerous cancers. The assay targets a well researched and understood metabolic pathway. BioMark of a few unique companies using safe therapeutic agents for diagnostic indication. As a non-invasive cost effective red alert tool, it is valuable to physicians around the world. It is a valuable tool for early stage cancer detection.
Urinary Excretion of Acetylamantadine by Cancer Patients
Principal Investigator: Dr. Andrew Maksymiuk, MD, Cancer Care Manitoba
Status: Open. In the process of final submission to Health Canada
Urinary Excretion of Acetylamantadine by Cancer Patients in Bangladesh
Principal Investigator: Prof. (Dr.) Parveen Shahida Akhtar, Head of the Department, Medical oncology,National Institute of Cancer Research and Hospital, Dhaka, Bangladesh
Status: Completed.
Food Effects on the Pharmacokinetics of Amantadine
Principal Investigator: Prof. Zeneng Cheng, Hunan Tiger-xiangya Drug Evaluation center, China
Status: Completed.
Urinary Excretion of Acetylamantadine by Normal Healthy Volunteers
Principal Investigator: Dr. Bram Ramjiawan, Ph. D, St. Boniface Hospital and Research Centre
Status: Completed.
Spermidine/spermine N-acetyltransferase 1 (SSAT 1) Gene Expression in Human Cancer
Principal Investigator: Dr. Andrew Maksymiuk, MD, Cancer Care Manitoba
Status: Open.
Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a Chemotherapy Regimen
Principal Investigator: Dr. Andrew Maksymiuk, MD, Cancer Care Manitoba
Co-Investigator: Dr. Daniel S. Sitar, Ph.D, University of Manitoba
Co-Investigator: Dr. Paramjit Tappia, Ph.D, Asper Clinical Research Institute
Status: Open. Mid point assessment to establish proof of concept and patients still being enrolled extended ethics approval
- Glioblastoma (GBM) Cancers
- Gastrointestinal Cancers
- Prostate and Head Cancers
- Neck Cancers
- Test as a “Red Alert”
- Measure response to treatment
- Monitor for recurrence for cancer survivors